United States-based Aquestive Therapeutics has entered into a settlement agreement resolving patent litigation related to Suboxone (buprenorphine and naloxone) Sublingual Film with Par Pharmaceuticals, an operating company of Endo International PLC and IntelGenx Technologies Corp, it was reported yesterday.

Indivior PLC and its US subsidiary, Indivior Inc, marketers and distributors of SUBOXONE, collaborated with partner Aquestive in the settlement with Par Pharmaceuticals Inc. According to the settlement agreement, Par Pharmaceuticals and IntelGenx agreed to introduce their proposed generic version of the buprenorphine and naloxone sublingual film no earlier than 1 January 2023.

The patent-infringement litigation is pending in the United States District Court for the District of Delaware. As required by law, both parties will submit the settlement agreement to the US Federal Trade Commission and the US Department of Justice for review.